All News

VERVE-102 reduced PCSK9 and LDL-C after one infusion in early Heart-2 data for patients needing additional lipid lowering.

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.

Orforglipron reduced body weight versus placebo in adults aged 65 years or older with obesity or overweight in ATTAIN-1 and ATTAIN-2.

DDW 2026: Laurie Keefer, PhD, discusses ASPIRE-CD findings on patient-reported outcomes, symptom improvement, and steroid-sparing care in Crohn disease.

FDA grants priority review to finerenone for adults with type 1 diabetes and chronic kidney disease based on FINE-ONE data.

Retatrutide reduced body weight by up to 28.3% at 80 weeks in adults with obesity or overweight in the phase 3 TRIUMPH-1 trial.

A NHANES analysis suggests a ferritin cutoff below 24 μg/L may identify more iron deficiency in children aged 5 to 14 years.

ACOG 2026: CDC data show many pregnancy-related deaths may be preventable through better care coordination, access, and follow-up.

Embedding addiction treatment in a resident primary care clinic increased confidence in SUD diagnosis, medication use, and harm-reduction counseling.

FDA approved baxdrostat for adults with hypertension not controlled on other agents, adding a new aldosterone-targeting option.

A 5-day course of ensitrelvir reduced symptomatic COVID-19 risk by 67% after household exposure in the phase 3 SCORPIO-PEP trial.

DDW 2026: Jennifer Schmaus, PhD, on how mental health screening in IBD clinics may improve engagement with psychogastroenterology services.

Despite waning direct impact of COVID-19, US pregnancy-related mortality remains higher than before the pandemic, driven by persistent cardiovascular, infectious, and hemorrhagic causes.

A large claims analysis suggests most US patients with prediabetes receive annual diabetes screening, although methods were not peer reviewed.

Colombel discusses 4-year LUCENT findings showing sustained disease clearance and a favorable long-term safety profile with mirikizumab in UC

Global experts have redefined PCOS as PMOS, spotlighting metabolic and heart risks to speed diagnosis, reduce stigma, and improve care.

Leslie Citrome, MD, on new NEI Spring Congress data on adjunctive lumateperone for major depressive disorder and how clinicians can weigh efficacy, tolerability, and next-step treatment decisions.

MR-100A-01 weekly contraceptive patch data will be presented ahead of an FDA decision on the investigational lower-estrogen product.